Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430014 · ClinicalTrials.gov registry record · Phase 1
Study of Atiprimod Treatment for Patients With Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00430014: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00430014 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430014, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Primary Objectives: The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer. Secondary Objectives: The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.
Interventions
- DRUG Atiprimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430014
The ClinicalTrials.gov registry entry for NCT00430014 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atiprimod is the first listed.
NCT00430014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430014 about?
NCT00430014 is a clinical study titled "Study of Atiprimod Treatment for Patients With Advanced Cancer". Primary Objectives: The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer. Secondary Objecti...
What is the current status of trial NCT00430014?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00430014?
The interventions under investigation include: Atiprimod (DRUG).
Who is sponsoring clinical trial NCT00430014?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.